Relmada Therapeutics Inc

NASDAQ:RLMD   12:59:00 PM EDT
19.02
-0.53 (-2.71%)
Earnings Announcements

Relmada Therapeutics Provides Corporate Update And Reports Third Quarter 2021 Financial Results

Published: 11/11/2021 21:09 GMT
Relmada Therapeutics Inc (RLMD) - Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results.
Q3 Loss per Share $2.44.
Q3 Revenue View $0.00 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.97

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.68

More details on our Analysts Page.